Capivasertib

Unassigned

New Medicines

Locally advanced or metastatic triple negative breast cancer

Information

New molecular entity
AstraZeneca
AstraZeneca

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

A small-molecule, oral Akt inhibitor
15% of patients with breast cancer have triple negative disease.
Locally advanced or metastatic triple negative breast cancer
Oral